布鲁克Announces Acquisition of MOLECUBES NV
GHENT, Belgium- 2021年11月19日 - 布鲁克公司（NASDAQ：BRKR）今天宣布收购MOLECUBES NV在台式临床前诊断动态创新者ear molecular imaging (NMI) systems. This acquisition strengthens Bruker’s position as a leading NMI solutions provider in preclinical and translational imaging research.
Bruker的临床前成像产品和全球足迹与模块化台式Cubes™Molecubes系统的结合将提供更广泛的NMI产品，以进一步在学术医疗中心和Biopharma公司中进一步加速全球NMI。
Dr. Wulf I. Jung, President of the Bruker BioSpin Preclinical Imaging Division commented: “Nuclear molecular preclinical and translational imaging research are growing market segments, in which we are already recognized for high-performance simultaneousPET/MR和PET/SPECT/CTinstruments, and for our PMOD™ PETdata analysis software. The acquisition of MOLECUBES adds scalable benchtop instruments to our portfolio for serving the NMI preclinical research community. The synergies between our and MOLECUBES’ research and development, applications and service teams is expected to benefit our combined NMI customers worldwide.”
Professor Roel Van Holen, CEO of MOLECUBES
作为一家快速发展的公司，成立于2015年在比利时的根特（Ghent），Molecubes开发和销售高端PET，SPECT和CT Cubes™系统，其全球安装基础在主要意见领导者中超过70个系统。模块化的台式立方体补充了布鲁克的集成，落地的临床前小动物成像系统。
MOLECUBES will remain an innovative and agile operational team within the Bruker BioSpin Preclinical Imaging division, and MOLECUBES customers can continue communications through existing channels. MOLECUBES’ R&D and applications teams will collaborate with Bruker’s preclinical imaging experts to continuously advance NMI technology, software, workflows and applications.
分子在2020财年收入中产生了约500万欧元。未披露收购的财务细节。有关更多信息，请访问www.fatactor.com/en/products-and-solutions/preclinical-imaging
About Bruker Corporation (Nasdaq: BRKR)
布鲁克is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity and customer success in life science molecular and cell biology research, in applied and pharma applications, in microscopy and nanoanalysis, as well as in industrial applications. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. Please visitwww.fatactor.com
关于分子
MOLECUBES in Ghent, Belgium is a manufacturer of molecular imaging instrumentation for preclinical research. MOLECUBES offers a modular benchtop platform, consisting of preclinical PET, SPECT and CT CUBES™ imagers. The CUBES form a scalable platform, enabling high throughput research with a compact footprint. MOLECUBES’ mission is to advance the imaging in preclinical settings with over 70 CUBES installed in leading research facilities within academic institutions, research hospitals, and biopharma companies and contract research organizations.www.molecubes.com
这立方体are compact micro-CT, micro-SPECT and micro-PET scanners for molecular small animal imaging, as standalone systems or in modular combinations:
- β立方 - 高性能临床前PET扫描仪
- X-CUBE – high-performance preclinical CT scanner
- γ-Cube - 高性能临床前SPECT扫描仪
布鲁克Investor Relations Contact
T: +1 (978) 663–3660, ext. 1479
E:Investor.Relations@bruker.com
媒体联系（布鲁克）
Thorsten Thiel博士
小组营销副总裁
Bruker Biospin
T: +49 (721) 5161-6500
E:pr@bruker.com
